Q-omics provides the consensus-scored MACO1 profile across patient tissues and cancer cell-line models. MACO1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MACO1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MACO1 RNA expression shows 20,084 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where MACO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MACO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MACO1 survival associations across molecular data types. MACO1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MACO1 RNA expression–survival associations across cancer types. High MACO1 expression shows unfavorable associations in KICH, SARC and CESC, but favorable associations in KIRC, LUAD and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MACO1 RNA expression.
This table summarizes MACO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MACO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MACO1 shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, BRCA, STAD and LUAD. The KIRC box plot shows higher MACO1 RNA expression in tumor versus normal tissue (log2 FC = +0.421, t-test p < 0.001).
This table shows molecular features associated with MACO1 in patient tissues and cancer cell lines. In patient samples, MACO1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MACO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
